Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap 
Investor Conference in New York
 
LOS ANGELES, CA -- (Marketwired) -- 04/13/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an
innovative biotechnology company developing bioelectronic products
and therapies for regenerative medicine, announced today that
Endonovo Chairman & CEO, Alan Collier, will present a company and
bioelectronics overview at the SeeThruEquity 5th Annual Microcap
Investor Conference on May 31, 2016. The event will be held at
Convene Conference Center at 730 3rd Avenue in New York City.
 
About Endonovo Therapeutics
 Endonovo Therapeutics, Inc. is an
innovative biotechnology company developing bioelectronic devices and
therapies for regenerative medicine. Endonovo's Immunotronics(TM)
platform is a non-invasive, non-implantable bioelectronic device for
treating/preventing vital organ failure through the reduction of
inflammation, cell death and the promotion of regeneration.
Endonovo's Cytotronics(TM) platform provides for a method of
expanding and manipulating cells using simulated microgravity and
Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering
and cell therapies. The Company's initial concentration is on the
treatment of acute and chronic inflammatory conditions of the liver
using its proprietary Immunotronics(TM) platform.
 
Safe Harbor Statement
 This press release contains information that
constitutes forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. All statements, trends, analysis, and other information
contained in this press release including words such as "anticipate,"
"believe," "plan," "estimate," "expect," "intend," and other similar
expressions of opinion, constitute forward-looking statements. Any
such forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from any future
results described within the forward-looking statements. Risk factors
that could contribute to such differences include those matters more
fully disclosed in the Company's reports filed with the Securities
and Exchange Commission. The forward-looking information provided
herein represents the Compa
ny's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press
release.
 
 
 
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108
Sbarnes@endonovo.com
www.endonovo.com
Investors: Sign Up for Email Alerts on Endonovo